Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline Review, H1 2015

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline Review, H1 2015', provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Basal Cell Carcinoma (Basal Cell Epithelioma) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Basal Cell Carcinoma (Basal Cell Epithelioma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Basal Cell Carcinoma (Basal Cell Epithelioma) Overview 8

Therapeutics Development 9

Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma)-Overview 9

Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma)-Comparative Analysis 10

Basal Cell Carcinoma (Basal Cell Epithelioma)-Therapeutics under Development by Companies 11

Basal Cell Carcinoma (Basal Cell Epithelioma)-Therapeutics under Investigation by Universities/Institutes 12

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Basal Cell Carcinoma (Basal Cell Epithelioma)-Products under Development by Companies 16

Basal Cell Carcinoma (Basal Cell Epithelioma)-Products under Investigation by Universities/Institutes 17

Basal Cell Carcinoma (Basal Cell Epithelioma)-Companies Involved in Therapeutics Development 18

4SC AG 18

Biofrontera AG 19

Biogenomics Limited 20

Biosceptre International Limited 21

Bristol-Myers Squibb Company 22

Genextra S.p.a. 23

MediGene AG 24

Novartis AG 25

Oncovir, Inc. 26

Redx Pharma Ltd 27

Transgene SA 28

Basal Cell Carcinoma (Basal Cell Epithelioma)-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Combination Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

aminolevulinic acid hydrochloride-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

BIL-010t-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

BMS-833923-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CIGB-128-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

CS-S/BCC-1-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

CS-TATI-1-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

DAC-060-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

erismodegib-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

interferon alfa-2b (recombinant)-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

LEQ-506-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Oshadi D + Oshadi R-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Poly-ICLC-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

sinecatechins-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecule to Inhibit Smoothened Receptor for Basal Cell Carcinoma-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecules to Inhibit Casein Kinase 1 for Cancer-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

TG-1042-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Basal Cell Carcinoma (Basal Cell Epithelioma)-Recent Pipeline Updates 62

Basal Cell Carcinoma (Basal Cell Epithelioma)-Dormant Projects 71

Basal Cell Carcinoma (Basal Cell Epithelioma)-Discontinued Products 72

Basal Cell Carcinoma (Basal Cell Epithelioma)-Product Development Milestones 73

Featured News & Press Releases 73

Mar 02, 2015: Basal Cell Carcinoma Drug Encourages Both Cancer Regression and Loss of Taste in Patients 73

Sep 17, 2014: Novartis presents oncology research advances with new data on sonidegib at ESMO 2014 73

Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma 74

Jun 01, 2014: Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma 74

May 23, 2014: Curis Announces Abstracts for Its Partnered Programs, Erivedge to be Presented at the 2014 ASCO Annual Meeting 75

Feb 19, 2014: Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma 76

Jul 15, 2013: Roche's Erivedge receives conditional EU approval for treatment of advanced basal cell carcinoma 77

Jun 11, 2013: Roche's Erivedge Gets Swiss Approval For Treatment Of Basal Cell Carcinoma 78

May 16, 2013: Curis Announces Presentation Of Erivedge Clinical Results At ASCO Annual Meeting 78

May 10, 2013: Curis Obtains Australian Approval For Erivedge For Treatment Of Adult Patients With Metastatic Basal Cell Carcinoma 78

Appendix 80

Methodology 80

Coverage 80

Secondary Research 80

Primary Research 80

Expert Panel Validation 80

Contact Us 80

Disclaimer 81

List of Tables

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2015 9

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by 4SC AG, H1 2015 18

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Biofrontera AG, H1 2015 19

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Biogenomics Limited, H1 2015 20

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Biosceptre International Limited, H1 2015 21

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Bristol-Myers Squibb Company, H1 2015 22

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Genextra S.p.a., H1 2015 23

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by MediGene AG, H1 2015 24

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Novartis AG, H1 2015 25

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Oncovir, Inc., H1 2015 26

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Redx Pharma Ltd, H1 2015 27

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Transgene SA, H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Assessment by Combination Products, H1 2015 30

Number of Products by Stage and Target, H1 2015 32

Number of Products by Stage and Mechanism of Action, H1 2015 34

Number of Products by Stage and Route of Administration, H1 2015 36

Number of Products by Stage and Molecule Type, H1 2015 38

Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics-Recent Pipeline Updates, H1 2015 62

Basal Cell Carcinoma (Basal Cell Epithelioma)-Dormant Projects, H1 2015 71

Basal Cell Carcinoma (Basal Cell Epithelioma)-Discontinued Products, H1 2015 72

List of Figures

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2015 9

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Targets, H1 2015 31

Number of Products by Stage and Top 10 Targets, H1 2015 31

Number of Products by Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 35

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35

Number of Products by Top 10 Molecule Types, H1 2015 37

Number of Products by Stage and Top 10 Molecule Types, H1 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

Biofrontera AG

Biogenomics Limited

Biosceptre International Limited

Bristol-Myers Squibb Company

Genextra S.p.a.

MediGene AG

Novartis AG

Oncovir, Inc.

Redx Pharma Ltd

Transgene SA

Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutic Products under Development, Key Players in Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics, Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Overview, Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline, Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com